Business Platform:
AllTranz will be a leader in the advancement of pain therapy by developing innovative prodrug strategies delivered via unique dermal delivery solutions to treat a variety of pain disorders. Potential new therapies include an array of neuroscience prodrugs as well as dermal delivery products. The AllTranz lead product is a proprietary synthetic cannabinoid for moderate to severe pain delivered via gel. The initial indication for the lead product is for the treatment of osteoarthritis. The AllTranz pipeline of products will target pain modulation, as well as substitution treatment for opiate addiction and alcohol abuse. The AllTranz technology addresses not only pharmacological limitations but the abuse potential and need for constant monitoring which confound the utility of current opioids. The intellectual property estate for AllTranz is based on discoveries made by Dr. Audra Stinchcomb, Founder and Chief Scientific Officer of AllTranz. Dr. Stinchcomb is actively engaged in leveraging chemical techniques to develop new prodrug formulations and drug delivery platforms using unique transdermal drug delivery vehicles.